UNITED STATES
                SECURITIES AND EXCHANGE COMMISSION
                      Washington, D.C. 20549

                           FORM 10-KSB

[X]    ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
       EXCHANGE ACT OF 1934

           For the fiscal year ended December 31, 2002


[ ]    TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES
       AND EXCHANGE ACT OF 1934

                 Commission file number 000-32363

                       CANCER CAPITAL CORP.
                       --------------------
      (Exact name of registrant as specified in its charter)

            Nevada                                      91-1803648
------------------------                   ----------------------------------
(State of incorporation)                  (I.R.S. Employer Identification No.)


2157 S. Lincoln Street, Salt Lake City, Utah       84106
----------------------------------------------     -----
(Address of principal executive offices)           (Zip code)

Issuer's telephone number, including area code: (801) 323-2395

Securities registered pursuant to Section 12(b) of the Act: None.

Securities registered pursuant to Section 12(g) of the Act: Common Stock

The issuer (1) filed all reports required to be filed by Section 13 or 15(d)
of the Securities Exchange Act of 1934 during the preceding 12 months (or for
such shorter period that the registrant was required to file such reports) and
(2) has been subject to such filing requirements for the past 90 days.
Yes [X]  No [ ]

Disclosure of delinquent filers in response to item 405 of Regulation S-B is
not contained herein, and will not be contained, to the best of registrant's
knowledge, in definitive proxy or information statements incorporated by
reference in Part III of this Form 10-KSB or any amendment to this Form
10-KSB.   [X]

State issuer's revenue for its most recent fiscal year: None.

As of March 4, 2003, the registrant had 5,150,000 shares of common stock
outstanding.  A market value of the 4,050,000 shares of voting stock held by
non-affiliates can not be determined because the registrant does not have an
active trading market.

Documents incorporated by reference: None.

Transitional Small Business Disclosure Format (check one): Yes [ ] No [X ]

<PAGE>
<PAGE>
                              PART I

Item 1.  Description of business...........................................3
Item 2.  Description of property...........................................6
Item 3.  Legal proceedings.................................................6
Item 4.  Submission of matters to a vote of security holders...............6

                             PART II

Item 5.  Market for common equity and related stockholder matters..........6
Item 6.  Plan of operation.................................................7
Item 7.  Financial statements..............................................7
Item 8.  Changes in and disagreements with accountants on accounting and
         financial disclosure.............................................18

                             PART III

Item 9.  Directors and executive officers; Compliance with Section 16(a)..18
Item 10. Executive compensation...........................................18
Item 11. Security ownership of certain beneficial owners and management...19
Item 12. Certain relationships and related transactions...................19
Item 13. Exhibits and reports on Form 8-K.................................20
Item 14. Controls and Procedures .........................................20
Signatures and Certifications ............................................21





                    FORWARD LOOKING STATEMENTS

     In this annual report references to "Cancer Capital," "we," "us," and
"our" refer to Cancer Capitol Corp.

     This annual report contains certain forward-looking statements and for
this purpose any statements contained in this annual report that are not
statements of historical fact may be deemed to be forward-looking statements.
Without limiting the foregoing, words such as "may," "will," "expect,"
"believe," "anticipate," "estimate" or "continue" or comparable terminology
are intended to identify forward-looking statements.  These statements by
their nature involve substantial risks and uncertainties, and actual results
may differ materially depending on a variety of factors, many of which are not
within Cancer Capital's control.  These factors include but are not limited to
economic conditions generally and in the industries in which Cancer Capital
may participate, competition within Cancer Capital's potential industry,
technological advances, and failure by Cancer Capital to successfully develop
business relationships.


                                2
<PAGE>

                              PART I

ITEM 1: DESCRIPTION OF BUSINESS

Historical Development

      We were incorporated in the state of Nevada on April 11, 1997, to
develop an alternative medical waste treatment and processing equipment
system.  We were unsuccessful in our efforts and are inactive at this time.

Our Plan

      We are a "blank check" company and have had recurring operating losses
for the past two fiscal years.  Our independent auditors have expressed doubt
that we can continue as a going concern unless we obtain financing to continue
operations.

      Our business plan is to seek, investigate, and, if warranted, acquire an
interest in a business opportunity.  Our acquisition of a business opportunity
may be made by merger, exchange of stock, or otherwise.  We have very limited
sources of capital, and we probably will only be able to take advantage of one
business opportunity. At the present time we have not identified any business
opportunity that we plan to pursue, nor have we reached any preliminary or
definitive agreements or understandings with any person concerning an
acquisition or merger.

       Based on current economic and regulatory conditions, management
believes that it is possible, if not probable, for a company like ours,
without many assets or liabilities, to negotiate a merger or acquisition with
a viable private company.  The opportunity arises principally because of the
high legal and accounting fees and the length of time associated with the
registration process of "going public."  However, should any of these
conditions change, it is very possible that there would be little or no
economic value for anyone taking over control of Cancer Capital.

      Our search for a business opportunity will not be limited to any
particular geographical area or industry and includes both U.S. and
international companies.  Our management has unrestricted discretion in
seeking and participating in a business opportunity, subject to the
availability of such opportunities, economic conditions and other factors.
Our management believes that companies who desire a public market to enhance
liquidity for current stockholders or plan to acquire additional assets
through issuance of securities rather than for cash will be potential merger
or acquisition candidates.

      The selection of a business opportunity in which to participate is
complex and extremely risky and will be made by management in the exercise of
its business judgement.  There is no assurance that we will be able to
identify and acquire any business opportunity which will ultimately prove to
be beneficial to Cancer Capital and our stockholders.  Should a merger or
acquisition prove unsuccessful, it is possible management may decide not to
pursue further acquisition activities and management may abandon its
activities and we may become dormant or be dissolved.

      Our activities are subject to several significant risks which arise
primarily as a result of the fact that we have no specific business and may
acquire or participate in a business opportunity based on the decision of
management which will, in all probability, act without consent, vote, or
approval of our stockholders.

      It is possible that the range of business opportunities that might be
available for consideration by us could be limited by impact of the SEC
regulations regarding purchase and sale of "penny stock."  Our common stock is
not publicly traded at this time and we cannot assure that a market will
develop or that a stockholder ever will be able to liquidate his investments
without considerable delay, if at all.  If a market develops, our shares will
likely be subject to the rules of the Penny Stock Suitability Reform Act of
1990. The liquidity of penny stock is affected by specific disclosure
procedures required by this Act to be followed by all broker-dealers,
including but not limited to,


                                3
<PAGE>

determining the suitability of the stock for a particular customer, and
obtaining a written agreement from the customer to purchase the stock.  This
rule may affect the ability of broker-dealers to sell our securities and may
affect the ability of purchasers to sell our securities in any market.

Investigation and Selection of Business Opportunities

      We anticipate that business opportunities will come to our attention
from various sources, including our officers and directors, our stockholders,
professional advisors such as attorneys and accountants, securities
broker-dealers, investment banking firms, venture capitalists, members of the
financial community and others who may present unsolicited proposals.
Management expects that prior personal and business relationships may lead to
contacts with these various sources.

      Our management will analyze the business opportunities; however, none of
our management are professional business analysts.  (See, Part III, Item 9:
"Directors and Executive Officers; . . .") Our management has had limited
experience with acquisitions or mergers of business opportunities and has not
been involved with an initial public offering.  John W. Peters, our President,
has been involved with acquisitions of subsidiaries as president of Earth
Products & Technologies, Inc.  These acquisitions were structured as
stock-for-stock exchanges between Earth Products and other operating
companies.  Due to our management's inexperience with acquisitions and
mergers, they may rely on promoters or their affiliates, principal
stockholders or associates to assist in the investigation and selection of
business opportunities.

      Certain conflicts of interest exist or may develop between Cancer
Capital and our officers and directors.  Our management has other business
interests to which they currently devote attention, which include their
primary employment and management of other blank check reporting companies.
They may be expected to continue to devote their attention to these other
business interests although management time should be devoted to our business.
As a result, conflicts of interest may arise that can be resolved only through
their exercise of judgement in a manner which is consistent with their
fiduciary duties to us.  In particular, Mr. Peters is a director of other
blank check companies with a structure and a business plan which is identical
to ours and he may in the future be involved with other blank check companies.
In the process of negotiations for an acquisition or merger or determination
of consulting fees related to investigation of a business opportunity, our
management and/or our principal stockholders may consider their own personal
pecuniary benefit or the interests of other blank check companies they are
affiliated with rather than the best interests of Cancer Capital's other
stockholders.

      We presently do not foresee entering into a merger or acquisition
transaction with any business with which our officers or directors are
currently affiliated. We may acquire or merge with companies of which our
management's affiliates or associates have a direct or indirect ownership
interest.  If we determine in the future that a transaction with an affiliate
would be in our best interest we are permitted by Nevada law to enter into
such a transaction if:

      (1)      The material facts regarding the relationship or interest of
the affiliate in the contract or transaction are disclosed or are known to the
Board of Directors.  The board authorizes the contract or transaction by the
affirmative vote of a majority of the disinterested directors, even though the
disinterested directors constitute less than a quorum; or

      (2)      The material facts regarding the relationship or interest of
the affiliate in the contract transaction are disclosed or are known to the
stockholders entitled to vote on the transaction, and the contract or
transaction is specifically approved by vote of the stockholders; or

      (3) The contract or transaction is fair to us at the time it is
authorized, approved or ratified by the Board of Directors or the
stockholders.
      A decision to participate in a specific business opportunity may be made
upon our management's analysis of the quality of the other company's
management and personnel, the anticipated acceptability of the business


                                4
<PAGE>

opportunity's new products or marketing concept, the merit of its
technological changes, the perceived benefit that it will derive from becoming
a publicly held entity, and numerous other factors which are difficult, if not
impossible, to analyze through the application of any objective criteria.  In
many instances, we anticipate that the historical operations of a specific
business opportunity may not necessarily be indicative of the potential for
the future because of the possible need to substantially shift marketing
approaches, significantly expand operations, change product emphasis, change
or substantially augment management, or make other changes.  We will be
dependent upon the owners of a business opportunity to identify any such
problems which may exist and to implement, or be primarily responsible for,
the implementation of required changes.

      In our analysis of a business opportunity we anticipate that management
will consider, among other things, the following factors:

      (1)   Potential for growth and profitability, indicated by a new
technology, anticipated market expansion, or new products;

      (2)   Our perception of how any particular business opportunity will be
received by the investment community and by our stockholders;

      (3)   Whether, following the business combination, the financial
condition of the business opportunity would be, or would have a significant
prospect in the foreseeable future of becoming sufficient to enable our
securities to qualify for listing on a exchange or on a national automated
securities quotation system, such as NASDAQ.

      (4)   Capital requirements and anticipated availability of required
funds, to be provided by us or from operations, through the sale of additional
securities, through joint ventures or similar arrangements, or from other
sources;

      (5)   The extent to which the business opportunity can be advanced;

      (6)   Competitive position as compared to other companies of similar
size and experience within the industry segment as well as within the industry
as a whole;

      (7)   Strength and diversity of existing management, or management
prospects that are scheduled for recruitment;

      (8)   The cost of our participation as compared to the perceived
tangible and intangible values and potential; and

      (9)   The accessibility of required management expertise, personnel, raw
materials, services, professional assistance, and other required items.

      No one of the factors described above will be controlling in the
selection of a business opportunity.  Management will attempt to analyze all
factors appropriate to each opportunity and make a determination based upon
reasonable investigative measures and available data. Potential business
opportunities may occur in many different industries and at various stages of
development.  Thus, the task of comparative investigation and analysis of such
business opportunities will be extremely difficult and complex. Potential
investors must recognize that because of our limited capital available for
investigation and management's limited experience in business analysis, we may
not discover or adequately evaluate adverse facts about the opportunity to be
acquired.

Form of Acquisition

      We cannot predict the manner in which we may participate in a business
opportunity. Specific business


                                5
<PAGE>

opportunities will be reviewed as well as our needs and desires and those of
the promoters of the opportunity.  The legal structure or method deemed by
management to be suitable will be selected based upon our review and our
relative negotiating strength. Such methods may include, but are not limited
to, leases, purchase and sale agreements, licenses, joint ventures and other
contractual arrangements. We may act directly or indirectly through an
interest in a partnership, corporation or other forms of organizations.  We
may be required to merge, consolidate or reorganize with other corporations or
forms of business organizations. In addition, our present management and
stockholders most likely will not have control of a majority of our voting
shares following a merger or reorganization transaction. As part of such a
transaction, our existing directors may resign and new directors may be
appointed without any vote by our stockholders.

      We likely will acquire our participation in a business opportunity
through the issuance of common stock or other securities.  Although the terms
of any such transaction cannot be predicted, it should be noted that issuance
of additional shares also may be done simultaneously with a sale or transfer
of shares representing a controlling interest by current principal
stockholders.

Competition

      We expect to encounter substantial competition in our effort to locate
attractive opportunities.  Business development companies, venture capital
partnerships and corporations, venture capital affiliates of large industrial
and financial companies, small investment companies, and wealthy individuals
will be our primary competition. Many of these entities will have
significantly greater experience, resources and managerial capabilities than
we do and will be in a better position than we are to obtain access to
attractive business opportunities.  We also will experience competition from
other public "blind check" companies, many of which may have more funds
available for such transactions.

Employees

      We currently have no employees.  Our management expects to confer with
consultants, attorneys and accountants as necessary.  We do not anticipate a
need to engage any full-time employees so long as we are seeking and
evaluating business opportunities.


                 ITEM 2: DESCRIPTION OF PROPERTY

      We do not currently own or lease any property.  Until we pursue a viable
business opportunity and recognize income, we will not seek independent office
space.


                    ITEM 3: LEGAL PROCEEDINGS

      We are not a party to any proceedings or threatened proceedings as of
the date of this filing.


   ITEM 4: SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

      We have not submitted a matter to a vote of our shareholders during the
fourth quarter of the 2002 fiscal year.


                             PART II

ITEM 5: MARKET PRICE FOR COMMON EQUITY AND RELATED STOCKHOLDER MATTERS

Market, Holders and Dividends

      We have no public market for our common stock as of the date of this
filing.  We have approximately 41



                                6
<PAGE>

stockholders of record holding 5,150,000 common shares.  Of these shares
1,150,000 shares are restricted stock as that term is defined in Rule 144 and
4,000,000 shares are unrestricted shares.  We have not declared dividends on
our common stock and do not anticipate paying dividends on our common stock in
the foreseeable future.

Securities Under Equity Compensation Plans

      We do not have any securities authorized for issuance under any equity
compensation plans.

Recent Sales of Unregistered Securities

      The following discussion describes all securities sold without
registration by Cancer Capital within the past three years.

      On June 30, 2000, we issued an aggregate of 200,000 shares valued at
approximately $2,000.  We issued 150,000 shares to John W. Peters and 50,000
shares were issued to L. Michelle Peters in consideration for services as our
officers. We relied on an exemption from registration provided by Section 4(2)
of the Securities Act for a private transaction not involving a public
distribution.

      On July 10, 2000, we issued 250,000 shares to The Oxford Group for
investment banking services valued at $5,000.  We relied on an exemption from
registration provided by Section 4(2) of the Securities Act for a private
transaction not involving a public distribution.


                    ITEM 6:  PLAN OF OPERATION

      We have experienced losses from inception and for the year ended
December 31, 2002, we had $1,861 cash on hand and $5,000 current liabilities.
Since inception, we have primarily financed our operations through equity
transactions by paying for services rendered by management and third parties
with common stock.

      We have no commitments for capital expenditures for the next twelve
months.  The majority of our expenses are related to our reporting obligations
under the Exchange Act.  We accrued $5,000 of expenses related to the
professional services required to prepare our reports and the costs of filing
the reports with the SEC.  We may repay these accounts payable with cash, if
available, or we may convert them into common stock. Also, if we acquire a
business opportunity we may incur additional reporting expenses related to
proxy or information statements we must provide to our stockholders which
disclose the company to be acquired's business operations, management and
financial condition.

       Our management intends to actively seek business opportunities during
the next twelve months. In the event we acquire a business opportunity we may
incur additional expenses related to proxy or information statements we must
provide to our stockholders which disclose that company's business operations,
management and financial condition.

      During the next twelve months we believe that our current cash needs can
be met by loans from our directors, officers and stockholders based on
informal understandings we have with these individuals.  These understandings
are not written agreements and therefore these persons are not obligated to
provide funds.  We may repay these loans and advancements with cash, if
available, or we may convert them into common stock.

       If we obtain a business opportunity, then it may be necessary to raise
additional capital through the sale of our common stock.  We intend to issue
such stock pursuant to exemptions provided by federal and state securities
laws.  The purchasers and manner of issuance will be determined according to
our financial needs and the available exemptions.  We do not currently intend
to make a public offering of our stock.  We also note that if we issue more
shares of our common stock our shareholders may experience dilution in the
value per share of their common stock.




                   ITEM 7: FINANCIAL STATEMENTS



                                7

<PAGE>











                       Cancer Capital Corp.

                       Financial Statements

                    December 31, 2002 and 2001

<PAGE> 8





                             CONTENTS


Independent Auditor's Report ...............................................3

Balance Sheets .............................................................4

Statements of Operations ...................................................5

Statements of Stockholders' Equity .........................................6

Statements of Cash Flows ...................................................7

Notes to the Financial Statements ..........................................8



<PAGE> 9




                      CHISHOLM & ASSOCIATES
A Professional           Certified Public Accountants    Office (801)292-8756
Corporation                    P.O. Box 540216              Fax (801)292-8809
                   North Salt Lake, Utah 84054
_____________________________________________________________________________


                   INDEPENDENT AUDITOR'S REPORT



To the Board of Directors and Stockholders
of Cancer Capital Corp.:

We have audited the accompanying balance sheets of Cancer Capital Corp. (a
development stage company) as of December 31, 2002 and 2001 and the related
statements of operations, stockholders' equity and cash flows for the years
ended December 31, 2002 and 2001 and from inception April 11, 1997 through
December 31, 2002.  These financial statements are the responsibility of the
Company's management.  Our responsibility is to express an opinion on these
financial statements based on our audits.

We conducted our audits in accordance with generally accepted auditing
standards in the United States of America.  Those standards require that we
plan and perform the audits to obtain reasonable assurance about whether the
financial statements are free of material misstatement.  An audit includes
examining, on a test basis, evidence supporting the amounts and disclosures in
the financial statements.  An audit also includes assessing the accounting
principles used and significant estimates made by management, as well as
evaluating the overall financial statement presentation.  We believe that our
audits provide a reasonable basis for our opinion.

In our opinion, the financial statements referred to above present fairly, in
all material respects, the financial position of Cancer Capital Corp.  (a
development stage company) as of December 31, 2002 and 2001 and the results of
its operations and cash flows for the years ended December 31, 2002 and 2001
and from inception April 11, 1997 through December 31, 2002 in conformity with
generally accepted accounting principles in the United States of America.

The accompanying financial statements have been prepared assuming that the
Company will continue as a going concern.  The Company has suffered recurring
losses from operations which raises substantial doubt about its ability to
continue as a going concern.  Management's plans in regard to these matters
are described in Note 2.  The financial statements do not include any
adjustments that might result from the outcome of this uncertainty.


/s/ Chisholm & Associates

Chisholm & Associates
North Salt Lake, Utah
January 2, 2003


<PAGE> 10




                       Cancer Capital Corp.
                  (A Development Stage Company)
                          Balance Sheets


                              ASSETS


                                                         December 31
                                                       2002         2001
                                                 ------------- --------------
CURRENT ASSETS

Cash (Note 1)                                    $      1,861  $       2,000
                                                 ------------- --------------

    TOTAL ASSETS                                 $      1,861  $       2,000
                                                 ============= ==============



               LIABILITIES AND STOCKHOLDERS' EQUITY


CURRENT LIABILITIES

Accounts Payable - related party                 $      5,000  $           -
                                                 ------------- --------------

STOCKHOLDERS' EQUITY

Common Stock, $.001 par value; 20,000,000
  shares authorized; 5,150,000 shares issued
  and outstanding                                       5,150          5,150

Additional Paid in Capital                             38,050         38,050

Deficit Accumulated during the development stage      (46,339)       (41,200)
                                                 ------------- --------------

  Total Stockholders' Equity (deficit)                 (3,139)         2,000
                                                 ------------- --------------

  TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY     $      1,861  $       2,000
                                                 ============= ==============






 The accompanying notes are an integral part of these financial statements

                               -4-

<PAGE> 11


                    Cancer Capital Corporation
                  (A Development  Stage Company)
                      Statement of Operations


                                                              From
                                     For the Years Ended      Inception on
                                         December 31          April 11, 1997
                                       2002        2001       to Dec. 31, 2002
                                  ------------- ------------- ----------------

REVENUES                          $          -  $         -  $            -
                                  ------------- ------------- --------------
EXPENSES

  General & Administrative               5,139             -         46,339
                                  ------------- ------------- --------------

    Total Expenses                       5,139             -         46,339
                                  ------------- ------------- --------------

Net Loss                          $     (5,139) $          -  $     (46,339)
                                  ============= ============= ==============

Net Loss Per Share                $      (0.00) $          -  $       (0.01)
                                  ============= ============= ==============
Weighted average shares
 outstanding                         5,150,000     4,918,056      4,810,191
                                  ============= ============= ==============















The accompanying notes are an integral part of these financial statements


                               -5-

<PAGE> 12


                       Cancer Capital Corp.
                  (A Development Stage Company)
                Statements of Stockholders' Equity
    From inception on April 11, 1997 through December 31, 2002




                                                                 Accumulated
                                                     Additional  During the
                                Common Stock         Paid in     Development
                             Shares       Amount     Capital     Stage
                           ------------- ----------- ----------- -------------
Common stock, issued at
 inception for cash at
 $.001 per share              1,000,000  $    1,000  $        -  $          -

Common stock, issued at
 inception for services
 at $.001 per share             200,000         200           -             -

Common stock issued for
 cash at $.01 per share       3,500,000       3,500      31,500             -

Net (loss) for the year
 ended December 31, 1997              -           -           -       (22,400)
                           ------------- ----------- ----------- -------------

Balance - December 31, 1997   4,700,000       4,700      31,500       (22,400)

Net (loss) for the year
 ended December 31, 1998              -           -           -        (9,900)
                           ------------- ----------- ----------- -------------

Balance - December 31, 1998   4,700,000       4,700      31,500       (32,300)

Net (loss) for the year
 ended December 31, 1999              -           -           -        (1,300)
                           ------------- ----------- ----------- -------------

Balance - December 31, 1999   4,700,000       4,700      31,500       (33,600)

Common stock issued for
 services at $.01 per share     200,000         200       1,800             -

Common stock issued for
 services at $.02 per share     250,000         250       4,750             -

Net (loss) for the year
 ended December 31, 2000              -           -           -        (7,600)
                           ------------- ----------- ----------- -------------

Balance - December 31, 2000   5,150,000       5,150      38,050       (41,200)

Net (loss) for the year
 ended December 31, 2001              -           -           -             -
                           ------------- ----------- ----------- -------------

Balance - December 31, 2001   5,150,000       5,150      38,050       (41,200)

Net (loss) for the year
 ended December 31, 2002              -           -           -        (5,139)
                           ------------- ----------- ----------- -------------

Balance - December 31, 2002   5,150,000  $    5,150  $   38,050  $    (46,339)
                           ============= =========== =========== =============





The accompanying notes are an integral part of these financial statements




                               -6-


<PAGE> 13


                       Cancer Capital Corp.
                  (A Development Stage Company)
                     Statement of Cash Flows



                                                             From
                                                             Inception on
                                      For the years ended    April 11, 1997
                                          December 31,       Through
                                        2002        2001     December 31, 2002
                                    ----------- ------------ -----------------
Cash Flows from Operating Activities

  Net Loss                          $   (5,139) $         -  $     (46,339)
  Adjustments for non-cash items:
    Increase in Accounts Payable         5,000            -          5,000
    Shares issued for services               -            -          7,200
                                    ----------- ------------ -----------------
  Net Cash Provided (Used) by
  Operating Activities                    (139)           -        (34,139)
                                    ----------- ------------ -----------------

Cash Flows from Investing Activities:        -            -              -
                                    ----------- ------------ -----------------
  Net Cash Provided (Used) in
  Investing Activities                       -            -              -
                                    ----------- ------------ -----------------
Cash Flows from Financing Activities:
  Issued common stock for cash               -            -         36,000
                                    ----------- ------------ -----------------
  Net cash Provided by
  Financing Activities                       -            -         36,000
                                    ----------- ------------ -----------------

Increase (Decrease) in Cash               (139)           -          1,861

Cash - beginning of period               2,000        2,000              -
                                   ------------ ------------ -----------------

Cash - end of period               $     1,861  $     2,000  $       1,861
                                   ============ ============ ==============

Supplemental Cash Flow Information:

  Cash Paid For:
    Interest                       $         -  $         -  $           -
    Income Taxes                   $         -  $         -  $           -


NonCash Financing Activities
     During 1997, 200,000 shares of common stock were issued at $.001 per
     share for services

     During 2000, 200,000 and 250,000 shares of common stock were issued for
     services at $.01 and $.02 per share, respectively






The accompanying notes are an integral part of these financial statements


                               -7-


<PAGE> 14





                       Cancer Capital Corp.
                  (A Development Stage Company)
                Notes to the Financial Statements
                    December 31, 2002 and 2001

NOTE 1 - Summary of Significant Accounting Policies

       a.  Organization & Consolidation Policy

           Cancer Capital Corp.  (the Company), was incorporated April 11,
1997 under the laws of the State of Nevada.   The Company was originally
formed for the purpose of developing an alternative medical waste treatment
system.  However, the Company in December 1997 abandoned this purpose and has
since been inactive.  The Company has never commenced any significant
activities or secured operations.  The Company is currently searching for
other business opportunities and is in the development stage according to
Financial Accounting Standards Board Statement No. 7.

       b.  Accounting Method

           The Company recognizes income and expense on the accrual basis of
accounting.

       c.  Earnings (Loss) Per Share


                                         Income (loss) Shares       Per Share
                                         (Numerator)  (Denominator) Amount
                                         ------------- ------------ ---------
For the year ended December 31, 2002:

 Basic EPS
  Income (loss) to common stockholders   $     (5,139)   5,150,000  $   (0.00)
                                         ============= ============ ==========
For the year ended December 31, 2001:

  Basic EPS
   Income (loss) to common stockholders  $          -    4,918,056  $       -
                                         ============= ============ ==========
From inception on April 11, 1997 to
December 31, 2002:

  Basic EPS
   Income (loss) to common stockholders  $   ( 46,339)   4,810,191  $   (0.01)
                                         ============= ============ ==========

           The computation of earnings per share of common stock is based on
the weighted average number of shares outstanding at the date of the financial
statements.

       d.  Cash and Cash Equivalents

           The Company considers all highly liquid investments with maturities
of three months or less to be cash equivalents.


                               -8-


<PAGE> 15




                       Cancer Capital Corp.
                  (A Development Stage Company)
                Notes to the Financial Statements
                    December 31, 2002 and 2001

NOTE 1 - Summary of Significant Accounting Policies (continued)

       e.  Provision for Income Taxes

           No provision for income taxes have been recorded due to net
operating loss carryforwards totaling approximately $46,300 will be offset
against future taxable income.  These NOL carryforwards began to expire in the
year 2017  No tax benefit has been reported in the financial statements
because the Company believes there is a 50% or greater chance the carryforward
will expire unused.

           Deferred tax asset and the valuation account is as follows as
December 31, 2002 and 2001:

                                                      December 31,
                                                  2002            2001
                                              -------------- --------------
 Deferred tax asset:
      NOL carryforward                        $      15,500  $       6,200

      Valuation allowance                          ( 15,500)       ( 6,200)
                                              -------------- --------------

                                              $           -  $           -
                                              ============== ==============

       f.  Use of estimates

           The preparation of financial statements in conformity with
generally accepted accounting principles requires management to make estimates
and assumptions that affect the reported amounts of assets and liabilities and
disclosure of contingent assets and liabilities at the date of the financial
statements and the reported amounts of revenues and expenses during the
reporting period.  Actual results could differ from those estimates.

NOTE 2 - Going Concern

           The accompanying financial statements have been prepared assuming
that the Company will continue as a going concern.  The Company has no assets
and has had recurring operating losses for the past several years and is
dependent upon financing to continue operations.  The financial statements do
not include any adjustments that might result from the outcome of this
uncertainty.  It is management's plan to find an operating company to merge
with, thus creating necessary operating revenue.

NOTE 3 - Development Stage Company

           The Company is a development stage company as defined in Financial
Accounting Standards Board Statement No. 7.  It is concentrating substantially
all of its efforts in raising capital and defining its business operation in
order to generate significant revenues.


                               -9-
<PAGE> 16

                       Cancer Capital Corp.
                  (A Development Stage Company)
                Notes to the Financial Statements
                    December 31, 2002 and 2001


NOTE 4 - Related Party Transactions

           During the year ended December 31, 2002, the Company incurred
$5,000 of professional fees payable to professionals affiliated with First
Equity Holdings Corp.  An officer of the Company is also an employee of First
Equity Holdings Corp.











                               -10-

<PAGE> 17


      ITEM 8: CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS
              ON ACCOUNTING AND FINANCIAL DISCLOSURE

      We have not had a change in, or disagreement with, our principal
independent accountant during the past two fiscal years.

                             PART III

ITEM 9: DIRECTORS AND EXECUTIVE OFFICERS; COMPLIANCE WITH SECTION 16(a)

      Our executive officers and directors and their respective ages,
positions and term of office are set forth below.  Biographical information
for each of those persons is also presented below.  Our bylaws require two
directors who serve for terms of one year or until they are replaced by a
qualified director.  Our executive officers are chosen by our Board of
Directors and serve at its discretion.  John and L. Michelle Peters are
married.

Name                Age      Position Held                      Director Since
------------------  -------  --------------------------------   --------------
John W. Peters       51      President and Director             April 11, 1997
L. Michelle Peters   50      Secretary/Treasurer and Director   April 11, 1997

      John W. Peters.   Mr. Peters has served as our President and a Director
since our inception.  Since July 1999 he has been the manager of Development
Specialties, Inc. a property management company.  From 1995 to the present he
has been President and Chairman of the Board of Earth Products and
Technologies, Inc, a reporting company.  He is a director of Bingham Canyon
Corporation and Skinovation Pharmaceutical, Inc., blank check reporting
companies.   Prior business experience includes Operations Manager for Earth
Products, President and Executive Officer of Certified Environmental
Laboratories, Inc. and Vice President of Sales and Marketing for Comco
Communications Corp. in California.  Mr. Peters studied business
administration at Long Beach Community College and California Polytechnic
State University in San Louis Obispo, California.

      L. Michelle Peters.  Mrs. Peters has served as our Secretary/Treasurer
and as a Director since our inception.  From 1997 to the present she has been
employed as a legal secretary for Thompson Hazer and Scoussen located in Salt
Lake City, Utah.  She was employed as a legal secretary by Parsons Behle &
Latimer from 1993 to 1997.  Mrs. Peters has 29 years of experience in the
legal profession as a legal secretary, paralegal and office administrator.


Section 16(a) Beneficial Ownership Reporting Compliance

      Section 16(a) of the Securities Exchange Act of 1934 requires our
directors, executive officers and persons who own more than ten percent of a
registered class of our equity securities, to file with the Securities and
Exchange Commission initial reports of ownership and reports of changes in
ownership of our common stock. Officers, directors and greater than
ten-percent beneficial owners are required by SEC regulations to furnish us
with copies of all Section 16(a) reports they file.  Based upon review of the
copies of such forms furnished to us during the fiscal year ended December 31,
2002 and representations to us that no Forms 5 were required, we believe no
reports were required to be filed for the year ended December 31, 2002.


                 ITEM 10: EXECUTIVE COMPENSATION

      Our named executive officers have not received any cash compensation,
bonuses, stock appreciation rights, long term compensation, stock awards or
long-term incentive rights in excess of $100,000 during the past three fiscal
years.  John W. Peters, who acts in the capacity similar to Chief Executive
Officer did not receive any compensation during the year ended December 31,
2002.  We have not entered into employment contracts with our executive
officers and their compensation, if any, will be determined at the discretion
of our Board of Directors.


                                18
<PAGE>

Compensation of Directors

      We do not have any standard arrangement for compensation of our
directors for any services provided as director, including services for
committee participation or for special assignments.


      ITEM 11: SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

      The following table sets forth the beneficial ownership of our
outstanding common stock by our management and each person or group known by
us to own beneficially more than 5% of our outstanding common stock.
Beneficial ownership is determined in accordance with the rules of the SEC and
generally includes voting or investment power with respect to securities.
Except as indicated by footnote, the persons named in the table below have
sole voting power and investment power with respect to all shares of common
stock shown as beneficially owned by them.  The percentage of beneficial
ownership is based upon 5,150,000 shares of common stock outstanding as of
March 4, 2003.

                    CERTAIN BENEFICIAL OWNERS

                                          Common Stock Beneficially Owned
                                          -------------------------------
Name and Address of            Number of Shares of
Beneficial Owners              Common Stock            Percentage of Class
---------------------          -------------------     -------------------
M. Jeanne Ball                     400,000                  7.8%
6071 Aries Drive
Salt Lake City, Utah 84118

Anita Patterson
588 NO West Capital
Salt Lake City, Utah 84103         400,000                  7.8%




                            MANAGEMENT

                                          Common Stock Beneficially Owned
                                          --------------------------------
Name and Address of             Number of Shares of
Beneficial Owners               Common Stock         Percentage of Class
--------------------------      -------------         ------------------
John W. Peters                     650,000                 12.6%
2157 S. Lincoln Street
Salt Lake City, Utah 84106

L. Michelle Peters                 450,000                  8.7%
2157 S. Lincoln Street
Salt Lake City, Utah 84106

All executive officers and
directors as a group               1,100,000               21.4%



     ITEM 12: CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS

      We have not engaged in any transactions in excess of $60,000 during the
past two years involving our executive officers, directors, 5% or more
stockholders or immediate family members of such persons.


                                19

<PAGE>


            ITEM 13: EXHIBITS AND REPORTS ON FORM 8-K

Exhibits

3.1      Articles of Incorporation (Incorporated by reference to exhibit 3.1
         to Form 10-SB, filed February 20, 2001)
3.2      Bylaws of Cancer Capital Corp. (Incorporated by reference to exhibit
         3.2 to Form 10-SB, filed February 20, 2001)
99.1     Section 1350 certification

Reports on 8-K

      None.

                 ITEM 14: CONTROLS AND PROCEDURES

      During the year ended December 31, 2002, we formalized the procedures we
rely on to ensure that material information regarding our company and its
operations is provided to the public in a timely manner.  On March 14, 2003,
our principal executive and financial officer, John W. Peters, evaluated the
effectiveness of these disclosure controls and procedures and determined that
there were no significant deficiencies in these procedures.

      Also, Mr. Peters did not identify any deficiencies or material
weaknesses in our internal controls, nor did he identify fraud that involved
management or other employees who had a significant role in our internal
controls.  He did not find any deficiencies or weaknesses which would require
changes to be made or corrective actions to be taken related to our internal
controls.


                                20


<PAGE>

                            SIGNATURES

      In accordance with Section 13 or 15(d) of the Exchange Act, the
registrant caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.


Date: March 17, 2003          Cancer Capital Corp.

                                  /s/ John W. Peters
                              By: ____________________________________________
                                  John W. Peters
                                  President, Principal Executive and Financial
                                  Officer and Director



      In accordance with the Exchange Act, this report has been signed below
by the following person on behalf of the registrant and in the capacities and
on the dates indicated.


                                  /s/ L. Michelle Peters
Date: March 17, 2003          By: ____________________________________________
                                  L. Michelle Peters
                                  Secretary/Treasurer and Director




            PRINCIPAL EXECUTIVE OFFICER CERTIFICATION


I, John W. Peters, certify that:

1.   I have reviewed this annual report on Form 10-KSB of Cancer Capital
Corp.;

2.   Based on my knowledge, this annual report does not contain any untrue
statement of a material fact or omit to state a material fact necessary to
make the statement made, in light of the circumstances under which statements
were made, not misleading with respect to the period covered by this annual
report;

3.   Based on my knowledge, the financial statements, and other financial
information included in this annual report, fairly present in all material
respects the financial condition, results of operations and cash flows of the
registrant as of, and for, the periods presented in this annual report.

4.   The registrant's other certifying officers and I are responsible for
establishing and maintaining disclosure controls and procedures (as defined in
Exchange Act Rules 13a-14 and 15d-14) for the registrant and we have:

a)   designed such disclosure controls and procedures to ensure that material
information relating to the registrant, including its consolidated
subsidiaries, is made known to us by others within those entities,
particularly during the period in which this annual report is being prepared;

b)   evaluated the effectiveness of the registrant's disclosure controls and
procedures as of a date within 90 days prior to the filing date of this annual
report (the "Evaluation Date"); and

                                21
<PAGE>


c)   presented in this annual report our conclusions about the effectiveness
of the disclosure controls and procedures based on our evaluation as of the
Evaluation Date;

5.   The registrant's other certifying officers and I have disclosed, based on
our most recent evaluation, to the registrant's auditors and the audit
committee of registrant's board of directors (or persons performing the
equivalent function):

a)   all significant deficiencies in the design or operation of internal
controls which could adversely affect the registrant's ability to record,
process, summarize and report financial data and have identified for the
registrant's auditors any material weaknesses in internal controls; and

b)   any fraud, whether or not material, that involves management or other
employees who have a significant role in the registrant's internal controls;
and

6.   The registrant's other certifying officers and I have indicated in this
annual report whether or not there were significant changes in internal
controls or in other factors that could significantly affect internal controls
subsequent to the date of our most recent evaluation, including any corrective
actions with regard to significant deficiencies and material weaknesses.


Date: March 17, 2003              /s/ John W. Peters
                                  ____________________________________
                                  John W. Peters
                                  Principal Executive Officer



            PRINCIPAL FINANCIAL OFFICER CERTIFICATION

I, John W. Peters, certify that:

1.   I have reviewed this annual report on Form 10-KSB of Cancer Capital
Corp.;

2.   Based on my knowledge, this annual report does not contain any untrue
statement of a material fact or omit to state a material fact necessary to
make the statement made, in light of the circumstances under which statements
were made, not misleading with respect to the period covered by this annual
report;

3.   Based on my knowledge, the financial statements, and other financial
information included in this annual report, fairly present in all material
respects the financial condition, results of operations and cash flows of the
registrant as of, and for, the periods presented in this annual report.

4.   The registrant's other certifying officers and I are responsible for
establishing and maintaining disclosure controls and procedures (as defined in
Exchange Act Rules 13a-14 and 15d-14) for the registrant and we have:

a)   designed such disclosure controls and procedures to ensure that material
information relating to the registrant, including its consolidated
subsidiaries, is made known to us by others within those entities,
particularly during the period in which this annual report is being prepared;

b)   evaluated the effectiveness of the registrant's disclosure controls and
procedures as of a date within 90 days prior to the filing date of this annual
report (the "Evaluation Date"); and

c)   presented in this annual report our conclusions about the effectiveness
of the disclosure controls and procedures based on our evaluation as of the
Evaluation Date;


                                22

<PAGE>

5.   The registrant's other certifying officers and I have disclosed, based on
our most recent evaluation, to the registrant's auditors and the audit
committee of registrant's board of directors (or persons performing the
equivalent function):

a)   all significant deficiencies in the design or operation of internal
controls which could adversely affect the registrant's ability to record,
process, summarize and report financial data and have identified for the
registrant's auditors any material weaknesses in internal controls; and

b)   any fraud, whether or not material, that involves management or other
employees who have a significant role in the registrant's internal controls;
and

6.   The registrant's other certifying officers and I have indicated in this
annual report whether or not there were significant changes in internal
controls or in other factors that could significantly affect internal controls
subsequent to the date of our most recent evaluation, including any corrective
actions with regard to significant deficiencies and material weaknesses.



Date: March 17, 2003                /s/ John W. Peters
                                    __________________________________
                                    John W. Peters
                                    Principal Financial Officer





                                24